...
search icon
ocul-img

Ocular Therapeutix Inc, Common Stock

OCUL

NMQ

$7.71

-$0.19

(-2.41%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.21B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.71M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.49
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.62 L
$11.78 H
$7.71

About Ocular Therapeutix Inc, Common Stock

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameOCULSectorS&P500
1-Week Return1.31%3.64%6.36%
1-Month Return2.39%-5.42%-5.32%
3-Month Return-2.28%-6.89%-8.86%
6-Month Return-30.79%-7.54%-5.61%
1-Year Return83.57%-1.81%8.61%
3-Year Return97.19%2.1%27.58%
5-Year Return36.22%35.25%90.38%
10-Year Return-68.52%88.1%160.03%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue17.40M43.52M51.49M58.44M63.72M[{"date":"2020-12-31","value":27.31,"profit":true},{"date":"2021-12-31","value":68.3,"profit":true},{"date":"2022-12-31","value":80.81,"profit":true},{"date":"2023-12-31","value":91.71,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue2.08M4.41M4.54M5.28M5.63M[{"date":"2020-12-31","value":37.02,"profit":true},{"date":"2021-12-31","value":78.31,"profit":true},{"date":"2022-12-31","value":80.7,"profit":true},{"date":"2023-12-31","value":93.87,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit15.32M39.12M46.95M53.16M58.10M[{"date":"2020-12-31","value":26.37,"profit":true},{"date":"2021-12-31","value":67.33,"profit":true},{"date":"2022-12-31","value":80.82,"profit":true},{"date":"2023-12-31","value":91.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin88.03%89.88%91.18%90.96%91.17%[{"date":"2020-12-31","value":96.54,"profit":true},{"date":"2021-12-31","value":98.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.76,"profit":true},{"date":"2024-12-31","value":99.99,"profit":true}]
Operating Expenses78.17M117.15M125.61M135.54M229.88M[{"date":"2020-12-31","value":34,"profit":true},{"date":"2021-12-31","value":50.96,"profit":true},{"date":"2022-12-31","value":54.64,"profit":true},{"date":"2023-12-31","value":58.96,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(62.85M)(78.04M)(78.65M)(82.38M)(171.78M)[{"date":"2020-12-31","value":-6284700000,"profit":false},{"date":"2021-12-31","value":-7803700000,"profit":false},{"date":"2022-12-31","value":-7865400000,"profit":false},{"date":"2023-12-31","value":-8238200000,"profit":false},{"date":"2024-12-31","value":-17178100000,"profit":false}]
Total Non-Operating Income/Expense(99.39M)64.85M1.39M(4.44M)(15.02M)[{"date":"2020-12-31","value":-153.27,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":2.15,"profit":true},{"date":"2023-12-31","value":-6.85,"profit":false},{"date":"2024-12-31","value":-23.16,"profit":false}]
Pre-Tax Income(155.64M)(6.55M)(71.04M)(80.74M)(193.51M)[{"date":"2020-12-31","value":-15563600000,"profit":false},{"date":"2021-12-31","value":-655300000,"profit":false},{"date":"2022-12-31","value":-7103800000,"profit":false},{"date":"2023-12-31","value":-8073600000,"profit":false},{"date":"2024-12-31","value":-19350600000,"profit":false}]
Income Taxes4.00M4.25M(7.62M)2.82M-[{"date":"2020-12-31","value":93.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-179.16,"profit":false},{"date":"2023-12-31","value":66.22,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(159.63M)(10.80M)(63.42M)(83.55M)-[{"date":"2020-12-31","value":-15963100000,"profit":false},{"date":"2021-12-31","value":-1080400000,"profit":false},{"date":"2022-12-31","value":-6342200000,"profit":false},{"date":"2023-12-31","value":-8355110500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(155.64M)(6.55M)(71.04M)(67.06M)(193.51M)[{"date":"2020-12-31","value":-15563600000,"profit":false},{"date":"2021-12-31","value":-655300000,"profit":false},{"date":"2022-12-31","value":-7103800000,"profit":false},{"date":"2023-12-31","value":-6705800000,"profit":false},{"date":"2024-12-31","value":-19350600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(159.63M)(10.80M)(63.42M)(80.74M)(193.51M)[{"date":"2020-12-31","value":-15963100000,"profit":false},{"date":"2021-12-31","value":-1080400000,"profit":false},{"date":"2022-12-31","value":-6342200000,"profit":false},{"date":"2023-12-31","value":-8073600000,"profit":false},{"date":"2024-12-31","value":-19350600000,"profit":false}]
EPS (Diluted)(2.47)(0.09)(0.96)(1.17)(1.47)[{"date":"2020-12-31","value":-247,"profit":false},{"date":"2021-12-31","value":-9,"profit":false},{"date":"2022-12-31","value":-96,"profit":false},{"date":"2023-12-31","value":-117,"profit":false},{"date":"2024-12-31","value":-147,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

OCUL
Cash Ratio 9.48
Current Ratio 10.66
Quick Ratio 10.59

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

OCUL
ROA (LTM) -30.53%
ROE (LTM) -95.21%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

OCUL
Debt Ratio Lower is generally better. Negative is bad. 0.31
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.69

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

OCUL
Trailing PE NM
Forward PE NM
P/S (TTM) 19.71
P/B 3.89
Price/FCF NM
EV/R 14.28
EV/Ebitda NM
PEG NM

FAQs

What is Ocular Therapeutix Inc share price today?

Ocular Therapeutix Inc (OCUL) share price today is $7.71

Can Indians buy Ocular Therapeutix Inc shares?

Yes, Indians can buy shares of Ocular Therapeutix Inc (OCUL) on Vested. To buy Ocular Therapeutix Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OCUL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ocular Therapeutix Inc be purchased?

Yes, you can purchase fractional shares of Ocular Therapeutix Inc (OCUL) via the Vested app. You can start investing in Ocular Therapeutix Inc (OCUL) with a minimum investment of $1.

How to invest in Ocular Therapeutix Inc shares from India?

You can invest in shares of Ocular Therapeutix Inc (OCUL) via Vested in three simple steps:

  • Click on Sign Up or Invest in OCUL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ocular Therapeutix Inc shares
What is Ocular Therapeutix Inc 52-week high and low stock price?

The 52-week high price of Ocular Therapeutix Inc (OCUL) is $11.78. The 52-week low price of Ocular Therapeutix Inc (OCUL) is $4.62.

What is Ocular Therapeutix Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ocular Therapeutix Inc (OCUL) is 3.89

What is the Market Cap of Ocular Therapeutix Inc?

The market capitalization of Ocular Therapeutix Inc (OCUL) is $1.21B

What is Ocular Therapeutix Inc’s stock symbol?

The stock symbol (or ticker) of Ocular Therapeutix Inc is OCUL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top